Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
회사 코드TAK
회사 이름Takeda Pharmaceutical Co Ltd
상장일May 16, 1949
설립일1925
CEOMr. Christophe Weber
직원 수- -
유형Depository Receipt
회계 연도 종료May 16
주소4F
도시CHUO-KU
증권 거래소NYSE Consolidated
국가Japan
우편 번호103-8668
전화81332782111
웹사이트https://www.takeda.com/
회사 코드TAK
상장일May 16, 1949
설립일1925
지난 5년 동안 총
1.42T
USD의 배당금이 분배되었습니다.
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024